Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): a Phase II, Single-Arm Trial

Colle E.; Besse B.

首页> 外文期刊>Oncologie. >Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): a Phase II, Single-Arm Trial

【24h】

Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): a Phase II, Single-Arm Trial

机译：抗PD-1免疫检查点抑制剂Nivolumab对晚期难治性鳞状非小细胞肺癌（CheckMate 063）患者的活性和安全性：II期单臂试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncologie.》 |2015年第8期|共2页
作者
Colle E.; Besse B.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 fre
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): a Phase II, Single-Arm Trial [J] . Colle E., Besse B. Oncologie. . 2015,第7a8期

机译：抗PD-1免疫检查点抑制剂Nivolumab对晚期难治性鳞状非小细胞肺癌（CheckMate 063）患者的活性和安全性：II期单臂试验
2. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J] . Horn Leora, Spigel David R., Vokes Everett E., Journal of Clinical Oncology . 2017,第35期

机译：Nivolumab对先前治疗的非小细胞肺癌患者的多西紫杉醇：两年随机，开放标签，第III期试验的两年成果（Checkmate 017和Checkmate 057）
3. 440?Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer [J] . Guo Gui Sun, Jing Hao Jia, Peng Gao, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：440？Camrelizumab的活性和安全性，抗PD-1免疫检查点抑制剂，用于晚期非小细胞肺癌患者
4. Activity and safety of nivolumab an anti-PD-1 immune checkpoint inhibitor for patients with advanced refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2 single-arm trial [O] . Naiyer A Rizvi, Prof. Julien Mazières, David Planchard, -1

机译：抗PD-1免疫检查点抑制剂nivolumab对晚期难治性鳞状非小细胞肺癌（CheckMate 063）患者的活性和安全性：第2阶段单臂试验
5. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis [O] . Koichi Ando, Ryo Manabe, Yasunari Kishino, 2020

机译：抗PD-1 / PD-L1免疫检查点抑制剂对难治性或复发先进的非小细胞肺癌的比较疗效和安全性 - 一种系统综述和网络元分析

Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): a Phase II, Single-Arm Trial

著录项

相似文献

相关主题

期刊订阅